natgillin/translations-raw huggingface dataset:
A pharmaceutical composition comprising the antibody of any one of claims 1-19, 22 and 27, or produced by the method of claim 26, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo prema bilo kojem od zahtjeva 1 do 4 ili 12 do 17, ili koje se proizvodi putem postupka prema zahtjevu 11, te farmaceutski prihvatljiv nosač.
reaction of a compound of formula II, wherein L1 represents a leaving group, and E, R2 and R3 are as defined in Claim 1, with a compound of formula III, wherein R1 is as defined in Claim 1; 
R* A . li pri čemu L' predstavlja izlaznu skupinu, i E, R* i R? su kako je definirano u zahtjevu 1, sa spojem s formulom III,
The compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical. 
Spoj prema zahtjevu 1 u obliku slobodne baze ili farmaceutski prihvatljive kiselinske adicijske soli, naznačen time, da se koristi kao farmaceutsko sredstvo.
A synthetic neural regeneration peptide (NRP) compound comprising a modified peptide domain APGR and/or a modified peptide domain RAGG, wherein the NRP compound is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. 
Spoj sintetičkog neuralnog regeneracijskog peptida (NRP), naznačen time, da sadrži modificiranu domenu peptida APGR i/ili modificiranu domenu peptida RAGG, gdje je spoj NRP odabran iz skupine koju čine SEQ ID NO:4, SEQ ID NO:5 i SEQ ID NO:6.
drying the obtained precipitate at a temperature ranging from room temperature to 40° C. under a pressure comprised between ambient pressure and under vacuum, for a duration of time ranging from 5 minutes to 1 day, 
– sušenja taloga na temperaturi u rasponu od sobne temperature do 40 °C pod tlakom u rasponu od okolišnog tlaka do 0,001 Torr (133,32 Pa), u trajanju u rasponu od 10 minuta do 1 dana.
In this situation the pressure in the pressure chamber 8 has a desired high level, and when the dispensing tap is opened the beverage is forced through the dispensing tube 10 while the container 2 collapses (not shown). 
U toj situaciji, pritisak u tlačnoj komori 8 ima željenu visoku razinu, i kad se pipac za točenje otvori, piće je prisiljeno da ide kroz cijev za točenje 10, pri čemu se spremnik 2 smanjuje (što nije prikazano) .
The process of any one of the preceding claims, further comprising a preliminary step of regulating and balancing the knitted fabric produced by the circular knitting machine (1), which preliminary regulating and balancing step is carried out before the cited process steps and comprises the additional steps of: 
Postupak sukladno bilo kojem od prethodnih Zahtjeva, nadalje sadrži preliminarni korak reguliranja I balansiranja pletene tkanine proizvedene pomoću kružnog stroja za pletenje (1), koji se korak preliminarnog reguliranja 1 balansiranja provodi prije koraka navedenog postupka I sadrži dodatne korake:
When the dispensing head is connected the pressure medium chamber is connected to the volume of beer in the keg. 
Kad je priključena glava raspršivača, tlačna komora medija je spojena na volumen piva u bačvici.
A compound according to claim 1 wherein R1a is methoxy, fluoro or cyano and R1b is hydrogen. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1a je metoksi, fluor ili cijano, a R1b je vodik.
The use according to claim 11 wherein migraine includes: transformed migraine or evolutive headache, cluster headache, tension headache as well as secondary headache disorders such as the ones derived from infections, metabolic disorders or other systemic illnesses and other acute headaches, paroxysmal hemicrania resulting from a worsening of the above mentioned primary and secondary headaches. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što migrena uključuje: transformoranu migrenu ili evolutivnu glavobolju, klaster glavobolju, tenzijsku glavobolju, kao i poremećaje sa sekundarnom glavoboljom, poput onih uzrokovanih infekcijama, metaboličkim poremećajima ili drugim sistemnim bolestima i druge akutne t2 HR P20100400 T1 glavobolje, paroksizmalnu hemikaniju do koje dolazi zbog pogoršanja gore navedene primarne i sekundarne glavobolje.
L-methionine at a concentration ranging from about 200 to about 400 mg/L; and a combination of ascorbic acid at a concetration ranging from about 10 to about 50 mg/L and of (+)-alpha-tocopherol at a concentration ranging from about 5 to about 25 mg/L. 
L-metionin u koncentraciji u rasponu od oko 200 do oko 400 mg/L; i kombinaciju askorbinske kiseline u koncentraciji u rasponu od oko 10 do oko 50 mg/L i of (+)-alfa-tokoferol u koncentraciji u rasponu od oko 5 do oko 25 mg/L.
The compound of any one of claims 1 to 7, wherein G2 is selected from the group below: wherein m is 1 and R3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino. 
(Rg)m A (Rom (Rom pri čemu m je 1 i Rs je izabran iz skupine koju čine hidroksi, hidroksimetil, amino, acilamino, acetilamino i metilamino.
transmitting from at least a portion of the pump stations status information indicating its respective pump standby status to a central controller, identifying the line section with which at least one pump station that is in standby is associated and that has the smallest diameter in comparison to the other line sections, with the group being formed from pump stations that are associated with this line section, 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da, za formiranje grupe, dio cjevovoda (SAj) se ustanovi s kojim je povezana barem jedna crpna stanica spremna za crpljenje koja ima najmanji promjer u odnosu na ostale dijelove cjevovoda (SA1...SA9), gdje se grupa formira od crpnih stanica (2) koje su povezane s tim dijelom cjevovoda (SA1...SA9).
The expansion joint according to claim 3, wherein the corrugation of the upper and lower plates is the same. 
Kompenzacijski spoj prema zahtjevu 3, naznačen time da je valovitost gornje (4) 1 donje ploče (5, 17) ista.
A wall structure according to claim 2, characterised in that in the wall plate (3, 3', 4, 4') 
Zidna struktura sukladno zahtjevu 1, naznačena time što u zidnoj ploči (3, 3’, 4, 4’)
R2c represents a hydrogen atom, a halogen atom, a hydroxy group, C1-6 alkyl which may be substituted by a fluorine atom or C1-6 alkoxy which may be substituted by a fluorine atom, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
R*" predstavlja atom vodika, atom halogena, hidroksi skupinu, C;.4 alkil koji može biti supstituiran atomom fluora ili Cig alkoksi koji može biti supstituiran atomom fluora, ili prolijek, ili farmaceutski prihvatljiva sol.
A compound of the following Formula (I), a pharmaceutically acceptable salt thereof: in the formula, 
Spoj sljedeće formule I). ili njegova farmaceutski prihvatljiva sol, za primjenu u prevenciji ili liječenju metaboličkog sindroma: u formuli,
The first endoscopic instrument may be a lens for viewing internal tissue or organs during operation or diagnosing, said instrument being coupled to a camera that may be connected to a television/screen. 
Ovaj prvi endoskopski instrument može biti leća za promatranje unutarnjeg tkiva ili unutarnjih organa za vrijeme operacije ili za vrijeme dijagnosticiranja, pri čemu je navedeni instrument spojen na kameru koja može biti spojena na televiziju/ekran.
A structural element (2, 3, 4, 5, 27, 30) as claimed in claim 6, wherein the structural element (2, 3, 4, 5, 27, 30) is a lower chassis (2) of the vehicle (1). 
Strukturni element (2, 3, 4, 5, 27, 30) u skladu s patentnim zahtjevom 6, naznačen time što je strukturni element (2, 3, 4, 5, 27, 30) donja šasija (2) vozila (1).
The inventive process for the preparation of crystallized polyethylene terephthalate, PET, which contains silicon bounded and integrated into the molecular structure of PET form, is characterized in that 
Izumiteljski proces za pripravu kristaliziranog polietilen tereftalata, PET-a, koji sadrži silikon u obliku vezanom i integriranom u molekulsku strukturu PET-a, karakteriziran je time što:
The ski boot according to one or more of the preceding claims, characterized in that said cuff (6) is adjustable in height due to the presence of a small tongue (35) adapted to be selectively made to protrude from the rear area of the upper perimetral edge (58) of said cuff (6) itself. 
Cipela za skijanje prema jednom ili više prethodnih zahtjeva, naznačena time, da se manžeti (6) može podesiti visina zbog prisutnosti malog jezička (35), koji je prilagođen selektivnoj izradi, tako da strši od stražnjeg područja gornjeg obodnog ruba (58) same manžete (6).
The pharmaceutical composition of unit dose according to claim 1, further comprising a pharmaceutically acceptable excipient. 
Farmaceutski sprej pripravak prema jednom od prethodnih zahtjeva, dalje sadrži farmaceutski prikladnu pomoćnu tvar kao manitol i/ili benzalkonijev klorid.
or two R9 groups taken together with the carbon atoms to which they are attached form a fused ring; and R17, for each occurrence, is independently an alkyl or an aralkyl. 
Ili dvije skupine Ry uzete zajedno sa ugljikovim atomom za koji su vezane čine spojeni prsten; i Ri7je u svakom slučaju nezavisno alkil ili aralkil.
The device of claims 1-5 or the use of claims 6-11 wherein each sponge has a length of 5 cm and width of 5 cm. 
Naprava iz patentnih zahtjeva 1-4 ili uporaba iz patentnih zahtjeva 5-10 pri čemu svaka spužva ima dužinu od 5 cm i širinu od 5 cm.
The composition according to any one of claims 1 or 2, characterized in that the calcium carbonate containing material is selected from precipitated calcium carbonate, natural calcium carbonate containing material and mixtures thereof. 
Pripravak prema bilo kojem od zahtjeva 1 ili 2, naznačen time da je materijal koji sadrži kalcijev karbonat odabran od istaloženog kalcijevog karbonata, prirodnog materijala koji sadrži kalcijev karbonat i njihovih smjesa.
The definition of “pharmaceutically acceptable” is meant to encompass any carrier, which does not interfere with effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which it is administered. 
HR P20070474 T3 Definicija "farmaceutski prihvatljiv" obuhvaća bilo koji nosač koji ne utječe na učinkovitost biološke aktivnosti aktivnog sastojka i nije toksičan za primatelja.
Further cells that are frequently used for the production of proteins intended for administration to humans are human cell lines such as the human fibrosarcoma cell line HT1080 or the human embryonic kidney cell line 293. 
Ostale stanice koje se često koriste u proizvodnji proteina namijenjenih primjeni na ljudima su humane stanične linije poput stanične linije humanog fibrosarkoma HT1080 ili stanične linije humanih stanica embrionalnog bubrega 293.
A process according to claim 6, wherein the reaction of the compound of formula I-2 with TiCl4 is performed at a temperature from 10 to 100° C. 
Postupak prema jednom od zahtjeva 7 do 9, naznačen time, da se reakcija spoja formule I-2 s TiCL,, izvodi na temperaturi od 10 do 100*C.
polymerizing N-carboxyanhydrides of tyrosine, alanine, Y-benzyl glutamate and N-trifluoroacetyl lysine to form protected glatiramer acetate; deprotecting protected glatiramer acetate with a solution of hydrobromic acid in acetic acid, the solution comprises less than 0.5% of free bromine and less than'1000 ppm of metal ion impurities, to form trifluoroacetyl glatiramer acetate; reacting trifluoroacetyl glatiramer acetate with aqueous piperidine to form a solution or glatiramer acetate; and 
Postupak za dobivanje farmaceutskog sastava koji sadrži glatiramer acetat, naznačen time, da sadrži a) polimeriziranje N- karboksianhidrida od tirozina, alanina, y-benzil glutamata i trifluoracetil lizina da bi se formirao zaštićeni glatiramer acetat; b) skidanje zaštite sa zaštićenog glatiramer acetata otopinom bromovodične kiseline u octenoj kiselini, koja je otopina prethodno obrađena hvatačem broma radi uklanjanja slobodnog broma, da bi se formirao trifluoracetil glatiramer acetat; €) dovođenje u reakciju trifluoracetil glatiramer acetata s vodenastim piperidinom, da bi se formirala otopina vodenastog glatiramer acetata; i d) pročišćavanje glatiramer acetata.
Composition according to any of the claims from 1 to 6, characterized in that binder is hydroxypropylmethylcellulose. 
Sastav prema bilo kojem od zahtjeva 1 do 5, naznačen time da je vezivo hidroksipropilmetilceluloza.
A composition as claimed in any one of claims 1 to 3 wherein the composition comprises 20 to 85g of ascorbate component, for example 25 to 75g, for example 20 to 60g, for example 50 to 60g. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što pripravak sadrži 20 do 85 g askorbata kao komponente, primjerice 25 do 75 g, primjerice 20 do 60 g, primjerice 50 do 60 g.
After stirring for 20 min (2-bromoethoxy)- t- butyldimethylsilane (10.0g, 46.4 mmol) was added dropwise over 20 min at 0 °C then the reaction heated to 70°C for 2.5 h. 
Nakon 20 minuta miješanja (2-brometoksi)-t- butildimetilsilan (10,0 g, 46,4 mmol) se ukapava 20 minuta na 0 "C, a zatim se reakcijsku smjesu grije 2,5 sati na 70 *C.
Alternatively, compounds of formula IV where L is oxygen or nitrogen, can be alkylated-, sulfonylated- or acylated using, for example, a base such as K2CO3 and an alkylating agent such as methyliodide or an aldehyde and reducing agent such as acetaldehyde and sodium cyanoborohydride and the like as described, for example, in Abdel-Magid, A. F. et al. 
Alternativno, spojevi formule IV gdje je L kisik ili dušik mogu se alkilirati, sulfonirati ili acilirati primjenom, npr., baze kao što je K2CO; i alkilirajućeg sredstva kao što je metiljodid ili aldehid i redukcijskog sredstva kao što je acetaldehid i natrijev cijanoborohidrid i slično kao što je opisano, npr., u Abdel-Magid, A_F.et al.
The method of claim 13, in which the melt is a glass melt which is formed in to mineral fibers selected from glass fibers, continuous glass fibers, glass wool fibers and stone wool fibers. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što je talina talina stakla, koju se oblikuje u mineralna vlakna, koja se bira između staklenih vlakana, kontinuiranih staklenih vlakana, vlakana za staklenu vunu i vlakana za kamenu vunu.
This was cooled, concentrated to remove acetone and extracted with CH2Cl2. 
Smjesa je hlađena, koncentrirana da bi se uklonio aceton i ekstrahirana sa CH2Cl2.
A composition for use according to Claim 1 or a composition as claimed in Claim 8, wherein the cyclodextrin is present in said aqueous solution at a concentration of from 25% to 40% (w/v) of the composition. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin prisutan u navedenoj vodenoj otopini u koncentraciji od 25% do 40% (tež./vol.) pripravka.
a viscosity modifier, optionally wherein said viscosity modifier is collagen, gellan gum, carbohydrate gel-forming polymers, carob bean gum, locust bean gum, carrageenan, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, guar gum, xanthan gum, carboxymethyl cellulose, clear starch, pectin, gelatin, arrowroot, cornstarch, katakuri starch, potato starch, sago, tapioca, furcellaran, or sodium pyrophosphate, optionally wherein said composition has a viscosity between about 1000 and about 10000 cP. 
(b) modifikator viskoznosti, proizvoljno kada je navedeni modifikator viskoznosti kolagen, gelan guma, ugljikohidratni polimeri koji tvore gel, guma od zrna karnaube, guma od rogača, karagenan, alginska kiselina, natrijev alginat, kalijev alginat, amonijev alginat, kalcijev alginat, agar, guar guma, ksantan guma, karboksimetil celuloza, čisti škrob, pektin, želatina, indijska maranta, kukuruzni škrob, katakuri škrob, škrob od krumpira, sago, tapioka, furcelaran, ili natrijev pirofosfat, proizvoljno kada navedeni pripravak ima viskoznost između oko 1000 1 oko 10000 cP.
Glatiramer acetate for use according to claim 2 or claim 3 for treating a human patient who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis. 
Glatiramer acetat za uporabu prema patentnom zahtjevu 1, naznačen time, da je čovjek kao pacijent već iskusio prvu kliničku epizodu i ustanovljeno je da je pod visokim rizikom za razvoj klinički definitivne multiple skleroze.
The hydrate of claim 1, which is characterized by a melting point of 220 to 224 °C, preferably 222 °C. 
Hidrat prema zahtjevu 1, koji je naznačen time da ima točku taljenja od 220 do 224 "€, poželjno 222 "C.
The compound for use according to claim 1, wherein the hyperproliferative disorder is ovarian cancer. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je hiper-proliferativni poremećaj rak jajnika.
The orthorhombic form can also be characterized by its crystallographic data. 
Ortorombski oblik može se također karakterizirati njegovim kristalografskim podacima.
R292P and V305I; at least one substitution of three amino acid residues, said substitutions being selected from the group consisting of: 
(C) najmanje jedne zamjene tri aminokiselinska ostatka, gdje se navedene zamjene bira iz skupine koju čine:
The method of claim 9 wherein the pharmaceutical composition is administered by a route selected from the group consisting of: transdermal, topical, oral, buccal, sublingual, intra venous, intra muscular, vaginal, rectal, ocular, nasal and follicular. 
Spoj za uporabu ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 10, naznačen time, da se spoj ili farmaceutski pripravak primjenjuje na način odabran iz skupine koju čine: topikalni, oralni, bukalni, sublingvalni, intravenozni, intramuskularni, vaginalni, rektalmi, okularni, nazalni i folikularni.
The method of claim 10, wherein the exogenous sequence encodes a protein that increases tolerance of the plant cell to the herbicide glyphosate. 
Postupak uklanjanja sekvence gena EPSPS iz genoma biljne stanice, naznačen time, da postupak obuhvaća sljedeće korake:
A composition comprising a recombinant glycosylated human Serum Amyloid P (SAP) polypeptide comprising an N-linked oligosaccharide chain, wherein at least one branch of the oligosaccharide chain terminates with an a2,3-linked sialic acid moiety, and wherein the composition has at least 50% fewer a2,6-linked sialic acid moieties than wild type SAP isolated from human serum. 
Glikolizirani humani serum amiloid P (SAP) polipeptid koji sadržava oligosaharidni lanac vezan na N, naznačen time, da najmanje jedan ogranak oligosaharidnog lanca završava s kiselinskim dijelom sijalične kiseline vezanim na a2,3.
The ophthalmic device of claim 18 wherein the ophthalmic device is selected from the group consisting of an intraocular lens; a contact lens; a keratoprosthesis; and a corneal inlay or ring. 
Očna naprava u skladu s patentnim zahtjevom 16, naznačena time što očna naprava se bira iz skupine koju čine intraokularna leća; kontaktna leća; keratoproteza; te kornealni umetak ili prsten.
contacting a peptide consisting of the candidate sequence selected in step (ii) with antigen presenting cells; 
(ill) stavljanja u kontakt peptida koji se sastoji od slijeda kandidata odabranog u koraku (ii) sa stanicama koje predočavaju antigene;
3 discloses side view of the box, where the following magnitudes are presented: 
3 otkriva bočni prikaz kutije, gdje su navedene sljedeće veličine:
Method according to any of the claims 1, wherein the aqueous solution comprising a dissolved salt of Micafungin or the aqueous solution in step b) of the present method comprises 2-30% v/v of a water miscible organic solvent. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina koja sadrži otopljenu sol Micafungina u koraku a) sadrži organsko otapalo koje se miješa s vodom u rasponu od 0 - 30 % v/v.
The variant of claim 1, wherein the reference anti-TNF-a antibody or reference anti-TNF-a binding fragment comprises a variable heavy chain fragment having an amino acid sequence corresponding to SEQ ID NO:2 and a variable light chain fragment having an amino acid sequence corresponding to SEQ ID NO:4. 
Varijanta iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da referentno anti-TNF-a, antitijelo ili fragment koji se veže referentnog anti-TNF-o antitijela sadržava varijabilni fragment teškog lanca koji ima aminokiselinsku sekvenciju koja odgovara SEQ ID NO:2 i varijabilni fragment lakog lanca koji ima aminokiselinsku sekvenciju koja odgovara SEQ ID NO:4.
The composition according to claim 1, wherein component (B2) is a fungicide selected from the group consisting of cyproconazole, propiconazole, and tebuconazole. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (B) odabrana iz skupine koja se sastoji od (Bl) strobilurin = fungicida - odabranog iz
Due to the lower pH, uptake of Ca and Mg is improved along the complete colon. 
Zahvaljujući nižem pH, povećava se pohrana Ca i Mg duž cijelog debelog crijeva.
An in vitro method for production of a full-length bispecific antibody comprising the following steps: incubating a first full-length antibody with a second full-length antibody under reducing conditions sufficient to allow reduction of the inter-chain disulfide bonds in the hinge region, and wherein the CH3 region of said first full-length antibody is a first CH3 region and has an Arg at position 409, and the CH3 region of said second full-length antibody is a second CH3 region and has: 
Postupak in vitro za proizvodnju bispecifičnog protutijela pune duljine, naznačen time, da obuhvaća sljedeće korake: a) inkubacija prvog protutijela pune duljine s drugim protutijelom pune duljine pod reduciranim uvjetima koji su dovoljni za omogućavanje redukcije međulančanih disulfidnih veza u zglobnom području, i pritom CH3-područje od navedenog prvog protutijela pune duljine je prvo CH3-područje i posjeduje Arg na poziciji 409, a CH3-područje od navedenog drugog protutijela pune duljine je drugo CH3-područje te posjeduje:
Method according to the claim 20 where the mixing of stabilized non smoking TCE and the air takes place in the exit (5) of the mixer (2). 
Metoda prema patentnom zahtjevu 17 gdje se miješanje kompozicije bazirane na bezvodnom kositar tetrakloridu 1 zraka odvija na izlazu (5) miješalice (2).
The method as claimed in claim 1, wherein the method further comprises applying cellulose fibers on the paper, before the heating of the décor and the paper with the resin. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja vlakana celuloze, poželjno vlakana alfa celuloze, na papir, prije zagrijavanja dekora (8).
contacting the intermediate of Formula VIII-R or VIII-S with substituted benzoic acid and a coupling reagent to form a compound of Formula IX-R or XI-S: 
(b) stavljanjem u kontakt međuprodukta Formule VIII-R ili VIII-S sa supstituiranom benzojevom kiselinom i konjugacijskim reagensom kako bi se dobilo spoj Formule TX-R ili IX-S:
wherein the VH or VL polypeptides contained in said antibody originated from one or more rabbit B cell populations. 
gdje VHiliVL lanci sadržani u navedenom protutijelu potječu iz jedne ili više populacije zečjih B stanica,
Such antibodies may be in the form of a human antibody, a humanized antibody, a chimeric human-murine antibody, murine, avian or other vertebrate antibody; or an antigen binding fragment thereof. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCLA/MIP-1$f,
Thus, in a preferred embodiment, the present process yields a composition that is essentially completely water soluble, meaning that said process comprises an additional step of removing and/or solubilising insoluble matter if this is required to achieve said water solubility. 
Dakle, u poželjnom ostvarenju, sadašnji postupak daje pripravak koji je uglavnom potpuno topljiv u vodi, što znači da spomenuti postupak sadržava dodatni korak uklanjanja i/ili solubiliziranja netopljive tvari ako je to potrebno za postizanje spomenute topljivosti u vodi.